WILLOW BIOSCIENCES INCORPORPORTS INSCRIPTA’S ONYX® PLATFORM to expand stress engineering capabilities and through

Calgary, dad And the Mountain View, California.And the 6 June 2022 / CNW / – Willow Biosciences Inc. (“willow“or the”a company(TSX: WLLW) (OTCQB: CANSF), a leading biotech company focused on revolutionizing the industrial manufacturing of pure, consistent and sustainable ingredients along with Inscripta®, the global leader in automated CRISPR-based gene editing technology, announced Today, Willow has integrated the Onyx genome engineering platform into its stress engineering workflows.

Willow Biosciences Inc. logo.  (CNW Group / Willow Biosciences Inc.)

Willow Biosciences Inc. logo. (CNW Group / Willow Biosciences Inc.)

Having previously been part of Inscripta’s Early Access program, Willow has a deep appreciation for the value that the ability to automated parallel parallel genome editing brings, especially to a simple biotech company. The integrated and intuitive interface of the tabletop tool Onyx uses best-in-class gene-editing technology, enabling scientists to perform multiplexed, whole-genome CRISPR modifications with the push of a button.

The Onyx platform will accelerate Willow’s gene-editing capabilities and throughput, positively impact commercial development timelines for FutureGrown™ molecules and reduce the time to market later. Integrating the Onyx platform into Willow’s proven workflow will enable her team to engineer strains more quickly, giving researchers invaluable time to focus on smart library design and data analysis.

“Technological advances such as next-generation sequencing have enabled researchers to read genetic information with incredible speed and depth. Inscripta technology now allows researchers to write genetic information at the same speed and with unparalleled accuracy, a combination that promises endless possibilities. It seamlessly integrates a high-throughput automated gene-editing platform from Inscripta to shorten our development cycles and enable our scientists to effectively harness the enormous potential of the entire genome.” Trish Choudaryvice president of research and development at Willow Biosciences.

“The future of the synthetic biology economy depends on both large and small companies innovating under increasing pressure to deliver better products, faster, and often with fewer resources. Willow is a great example of how an agile and highly innovative organization can quickly integrate and use the Onyx platform,” said Dr. Nandini KrishnamurthyVice President of the Microbial Business Unit at Inscripta. “We look forward to working with the team at Willow to increase stress performance while shortening development timelines.”

About Willow Biosciences Inc.

Willow develops and produces high-purity ingredients for the personal care, food and beverage, and pharmaceutical markets. Willow’s FutureGrown biotech platform allows production at scale with sustainability at its core. Willow’s R&D team has a proven track record of developing and marketing critical manufacturing processes and products to benefit our business partners and their customers.

For more information, please visit www.willowbio.com.

About Inscripta

Inscripta® is a life sciences technology company that enables scientists to solve some of today’s most pressing challenges using the first on-the-table genome editing system. company mechanism Onyx® platformConsisting of a tool, consumables, assays, and software, CRISPR-based genome engineering makes accessible to any research laboratory. Inscripta supports its customers all over the world from the facilities located in Boulder, Colorado; San Diego And the Pleasanton, California; And the Copenhagen, Denmark.

To find out more, visit Inscripta.com and follow Tweet embed or call

Michael B
Vice President of Marketing

forward-looking statements

This press release may contain forward-looking statements including opinions, assumptions, estimates, and the Company’s evaluation of future plans and operations, and, more specifically, statements regarding: Willow’s ability to expand gene-editing capabilities and productivity and the positive impact on commercial development schedules of FutureGrown™ molecules; The company’s business plan. When used in this press release, the words “will,” “expect,” “believe,” “estimate,” “expect,” “intent,” “may,” “project,” “should,” and similar expressions to be among the statements. that identify forward-looking statements. Forward-looking statements are based on expectations and assumptions made by the Company which include, but are not limited to: the success of Willow’s strategic partnerships, including the development of future strategic partnerships; the financial strength of the company; The company’s ability to fund its business plan using available cash and existing resources; Willow Products Market; The Company’s ability to obtain and maintain applicable licenses; The company’s ability to obtain suitable manufacturing partners and other strategic relationships; and successful implementation of the overall Willow production and marketing strategy. Forward-looking statements are subject to a wide range of risks and uncertainties, and although the Company believes that the expectations represented by such forward-looking statements are reasonable, there can be no guarantee that such expectations will be achieved. Any number of significant factors could cause actual results to differ materially from those in the forward-looking statements including, but not limited to, risks associated with: the biotechnology industry in general; the success of the company’s research and development strategies; infringement of intellectual property; Not benefiting from partnerships or successfully merging acquisitions; actions and initiatives of federal and provincial governments and changes in government policies, implementation and impact of such actions, initiatives and policies; competition from other industry participants; adverse US, Canadian, and global economic conditions; Adverse global events and public health crises, including the current COVID-19 outbreak; non-compliance with certain regulations; The departure of key management personnel or the inability to attract and retain talent; and other factors fully described from time to time in the reports and filings of the Company with the securities regulatory authorities. Please refer to the most recent annual company information form and management discussion and analysis for additional risk factors related to Willow, which can be accessed either on the Willow website at www.willowbio.com or under the company profile at www.sedar.com.

Any future-oriented financial projections and information contained in this document regarding potential financial performance, financial position, cash balances, or revenue are based on assumptions about future events, including economic conditions and proposed courses of action based on management’s assessment of relevant information that is currently available. . Expected operating information contains forward-looking information and is based on a number of assumptions and material factors, as described above. These forecasts may also be thought of as containing future-oriented financial information or financial projections. Actual results of the Company’s operations for any period are likely to differ from the amounts stated in these forecasts and such differences may be material. Actual results will differ from expected results. Readers are cautioned that any financial projections or future financial information contained in this document should not be used for purposes other than those disclosed here.

The forward-looking statements contained in this press release are made as of the date of this release and the Company undertakes no obligation to publicly update or revise any of the forward-looking statements included, except as required by applicable law. The forward-looking statements made here are expressly conditioned on this cautionary statement.



View original content for multimedia download:https://www.prnewswire.com/news-releases/willow-biosciences-incorporates-inscriptas-onyx-platform-to-expand-strain-engineering-capabilities-and-throughput-301561340.html

Source: Willow Biosciences Inc.



View original content for multimedia download: http://www.newswire.ca/en/releases/archive/June2022/06/c8955.html